Received Apr 22, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | KD27Z | — |
Twinrix underage administration to a 17-year-old patient.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 17-year-old male patient who received HAB (Twinrix) (batch number KD27Z, expiry date 08-SEP-2028) for prophylaxis. On 13-APR-2026, the patient received Twinrix. On 13-APR-2026, an unknown time after receiving Twinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Twinrix underage administration to a 17-year-old patient.). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 15-APR-2026 The medical assistant reported the Twinrix vaccine was administered to a patient at inappropriate age.